Table 3.
ESR1 c.454-351A>G (XbaI) | ||||||
---|---|---|---|---|---|---|
Genotype Frequencies (%) | Allele Frequencies (%) | |||||
GG | GA | AA | G * 1000Genomes: 30.8% |
A * 1000Genomes: 69.2% |
||
IBD (all patients) n = 198 |
21 (9.6%) | 98 (49.0%) | 79 (41.4%) | 140 (35.4%) | 256 (64.6%) | |
UC patients (n = 98) | 11 (11.2%) | 47 (48.0%) | 40 (40.8%) | 69 (35.2%) | 127 (64.8%) | |
CD patients (n = 100) | 10 (10.0%) | 51 (51.0%) | 39 (39.0%) | 71 (35.5%) | 129 (64.5%) | |
CG (n = 41) | 2 (4.9%) | 19 (46.3%) | 20 (48.8%) | 23 (28.0%) | 59 (72.0%) | |
Comparisons of allelic and genotypic frequencies between groups under study | ||||||
[GG + GA] vs. [AA] | [GG] vs. [GA + AA] | [GG] vs. [AA] | [G] vs. [A] | [A] vs. [G] | ||
CG vs. IBD OR, 95% CI P-value |
OR = 0.70 CI = [0.36–1.37] P = 0.293 | OR = 2.31 CI = [0.52–10.28] P = 0.258 | OR = 2.66 CI = [0.58–12.29] P = 0.196 | OR = 1.40 CI = [0.83–2.37] | OR 0.71 CI = [0.42–1.20] | |
P = 0.204 | ||||||
CG vs. UC OR, 95% CI P-value |
OR = 0.72 CI = [0.35–1.51] P = 0.387 | OR = 2.47 CI = [0.52–11.65] P = 0.241 | OR = 2.75 CI = [0.56–13.61] p = 0.201 | OR = 1.39 CI = [0.79–2.45] | OR = 0.71 CI = [0.41–1.26] | |
P = 0.248 | ||||||
CG vs. CD OR, 95% CI P-value |
OR = 0.67 CI = [0.32–1.40] P = 0.285 | OR = 2.17 CI = [0.45–10.35] P = 0.322 | OR = 2.56 CI = [0.51–12.84] P = 0.239 | OR = 1.412 CI = [0.81–2.48] | OR = 0.71 CI = [0.40–1.24] | |
P = 0.228 | ||||||
CD vs. UC OR, 95% CI P-value |
OR = 0.93 CI = [0.53–1.64] P = 0.794 | OR = 0.88 C.I. = [0.36–2.17] P = 0.780 | OR = 0.932 CI = [0.36–2.44] P = 0.887 | OR = 1.01 CI = [0.67–1.53] | OR = 0.99 CI = [0.65–1.49] | |
P = 0.951 |
No corrections for the multiple statistical testing were made. CG—control group, [GG + GA] vs. [AA]—dominant model, risk allele: G, [GG] vs. [GA + AA]—recessive model, risk allele: A, * Allele frequencies for European population according to 1000Genomes Project have been gathered from https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=ss1322898670 website [42].